Related references
Note: Only part of the references are listed.Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma
Hans C. Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
The PtdIns3-phosphatase MTMR3 interacts with mTORC1 and suppresses its activity
Feike Hao et al.
FEBS LETTERS (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Takumi Ito et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma
Agoston Gyula Szabo et al.
LEUKEMIA & LYMPHOMA (2016)
Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition
Hongyuan Chang et al.
NUCLEIC ACIDS RESEARCH (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Cereblon binding molecules in multiple myeloma
K. M. Kortuem et al.
BLOOD REVIEWS (2015)
A Phase I Dose-Escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC-223 in Patients With Advanced Solid Tumors or Multiple Myeloma
Johanna C. Bendell et al.
CANCER (2015)
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
Elias E. Stratikopoulos et al.
CANCER CELL (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
Andreas Guenther et al.
HAEMATOLOGICA (2015)
The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma
Bingzong Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
Andreas Guenther et al.
HAEMATOLOGICA (2015)
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma
Isabella C. Glitza et al.
LEUKEMIA & LYMPHOMA (2015)
mLST8 Promotes mTOR-Mediated Tumor Progression
Kyoko Kakumoto et al.
PLoS One (2015)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer et al.
BLOOD (2014)
The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy
Naohiro Sekiguchi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
M. Affer et al.
LEUKEMIA (2014)
\ Bromodomain and Extraterminal Domain Inhibitors (BETi) for Cancer Therapy: Chemical Modulation of Chromatin Structure
Jun Qi
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
B. A. Walker et al.
BLOOD CANCER JOURNAL (2014)
Impact of MYC on malignant behavior
German Ott
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Targeting PI3K/mTOR signaling in cancer
Alexandre Arcaro
FRONTIERS IN ONCOLOGY (2014)
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
Teresa S. Hawley et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation
Jing Lu et al.
BLOOD (2013)
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
Wen Zhou et al.
CANCER CELL (2013)
Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
Shwu-Yuan Wu et al.
MOLECULAR CELL (2013)
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
Anastasia Wyce et al.
PLOS ONE (2013)
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
Michael Pourdehnada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Role of PRAS40 in Akt and mTOR signaling in health and disease
Claudia Wiza et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
Deborah J. Kuhn et al.
BLOOD (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL
G. Hutter et al.
LEUKEMIA (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Chad C. Bjorklund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
Gabriele Buda et al.
ANNALS OF HEMATOLOGY (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Pim kinase-dependent inhibition of c-Myc degradation
Y. Zhang et al.
ONCOGENE (2008)
Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1
Jidong Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding
Lifu Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma
Hashem Younes et al.
CLINICAL CANCER RESEARCH (2007)
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
Raoul Tibes et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Development of protacs to target cancer-promoting proteins for ubiquitination and degradation
KM Sakamoto et al.
MOLECULAR & CELLULAR PROTEOMICS (2003)
GATA-2/estrogen receptor chimera regulates cytokine-dependent growth of hematopoietic cells through accumulation of p21WAF1 and p27Kip1 proteins
S Ezoe et al.
BLOOD (2002)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
YP Shou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
